 |
combination of sodium phenylbutyrate and tauroursodeoxycholic acid dihydrate |
|---|---|
| Trade Name | |
| Orphan Indication | Amyotrophic lateral sclerosis |
| USA Market Approval | USA |
| USA Designation Date | 2017-07-27 00:00:00 |
| Sponsor | Amylyx Pharmaceuticals Inc.;210 Broadway, Suite 201;Cambridge, Massachusetts, 02139 |
